New Target Cuts SARS-CoV-2 Replication in Cells
Targeting conserved viral interactions could support broader antivirals, though the approach has only been tested in cell cultures so far.
Updated on Nov. 2, 2026 in Life Sciences
Live Poll
Should the government increase funding for research preparing for future pandemics?
Researchers at UC Riverside and UC San Diego identified previously unknown interactions between SARS-CoV-2 viral RNA and proteins, and disrupting them significantly reduced viral replication in cell cultures. The work is research-stage: it has been tested in cell cultures, not in animals or people.
Why it matters
SARS-CoV-2 accumulates mutations quickly, which can reduce the effectiveness of treatments designed to recognize its changing features. Targeting conserved RNA-protein interaction sites offers a possible route to broader antivirals, a direction a 2024 Nature Reviews Microbiology review also highlighted.
The study mapped protein-RNA interactions across the SARS-CoV-2 genome using eCLIP, then tested antisense oligonucleotides against the newly identified sites in Vero cells and human lung cells. Replication was significantly reduced in both cell types, but the source reports no quantified percentage, so the magnitude of the effect remains unspecified.
The players
University of California, Riverside
A public research university whose scientists co-led the study identifying SARS-CoV-2 RNA-protein interactions.
University of California, San Diego
A public research university whose scientists co-led the study and contributed to mapping viral RNA-protein interactions.
The details
The team used enhanced cross-linking and immunoprecipitation (eCLIP), a method that chemically locks proteins to the RNA they touch so they can be mapped, to chart where viral proteins bind the virus's genetic material. They found that the nucleocapsid (N) protein binds the 5' untranslated region of the viral genome, which appears to influence translation, and that the RNA-dependent RNA polymerase (RdRp) binds the RNA encoding the viral protein NSP3. Antisense oligonucleotides, short synthetic strands of genetic material designed to bind matching sequences, were built to block these sites and reduced viral replication.
Timeline
2024: A Nature Reviews Microbiology review highlighted broad-spectrum antivirals targeting conserved viral components.
- 2026-11-02
Drug Target Review published the study findings.
The Tech Race
The work targets conserved viral components, the direction a 2024 Nature Reviews Microbiology review pointed to as a route to broad-spectrum antivirals. Xiang is investigating similar RNA-protein interactions in other viruses, and Yeo's group continues developing technologies for mapping these relationships.
This work is at the cell-culture stage, so no treatment is available to patients and no timeline for human use has been announced. Any therapeutic path would first require animal studies, which the researchers identify as an important next step.
The takeaway
The approach suggests antivirals aimed at conserved viral machinery could outpace mutation-driven resistance. Watch for animal study results, which the researchers identify as the next required step before any therapeutic development.
Further reading
Explore more research on Life Sciences advances from across California's universities.
Source note: This article includes information reported by Drug Target Review.
Live Poll
Should the government increase funding for research preparing for future pandemics?
